参麦注射液对扩张型心肌病sICAM-1水平的影响

目的探讨扩张型心肌病（DCM）的发病机制及参麦注射液对扩张型心肌病患者抗黏附治疗的有效性。方法用酶联免疫吸附法测定40倒扩张型心肌病患者及25例健康对照组sICAM-1水平，并将DCM患者随机分为常规治疗组（20例）和参麦治疗组（20例），常规治疗组予常规治疗，参麦治疗组在常规治疗的基础上加用参麦注射液，同时监测治疗前后血清sICAM-1水平的变化。结果扩张型心肌病患者血清siCAM-1（121．21±43．55）ng／ml明显高于对照组（60．76±21．85）ng／ml（P〈0．01）；参麦治疗组sICAM-1水平由治疗前的（120．77±33．87）ng／ml下降到治疗后的（62．21±23．43）ng／ml；常规治疗组siCAM-1水平由治疗前的（121．64±52．40）ng／ml下降到治疗后的（95．99±24．65）ng／ml，但无统计学意义（P〉0．05），且治疗后参麦治疗组sICAM1水平明显低于同期常规治疗组（P〈0．05）。结论扩张型心肌病患者血清中sICAM-1高表达，参麦注射液能明显降低扩张型心肌病患者血清sICAM-1含量，具有抗黏附作用，能够抑制血管壁炎症、保护血管内皮细胞。

Effect of Shenmai injection on sICAM-1 in patients with dilated cardiomyopathy

Objective To study the effect of Shenmai injection on sICAM-1 in patients with dilated cardiomyopathy. Methods With enzymelinked immunosorbent assay（ ELISA）, serum levels of soluble intercellular adhesion molecule- I（sICAM-1） was measured in the sera from 40 patients with dilated cardiomyopathy （DCM） and 25 healthy people. Forty patients were divided into two groups, including control group treated with conventional medicine （20 patients） and SMI group treated with conventional medicine plus SMI （20 patients）, sICAM-1 was measured before and after treatment. Results sICAM- 1 in patients with DCM （121.21±43.55） ng/ml was increased compared with health people （60.76±21.85） ng/ml （P〈0.01）. sICAM - I in SMI group after treatment（120.77±33. 87）ng/ml decreased more significantly than that before treatment（62.21±23.43）. Conclusion Serum soluble intercellular adhesion molecule- 1 was high in patients with dilated cardiomyopathy. SMI can attenuate serum sICAM-1 in patients with dilated cardiomyopathy.